NEWTON, Mass.--(BUSINESS WIRE)--Tryton Medical, Inc., the leading developer of stents designed to treat bifurcation lesions, announced it completed the enrollment phase of the Tryton First-in-Man (FIM) Study. The multi-center clinical trial evaluated the safety of Tryton’s Side-Branch Stent in the treatment of coronary bifurcation lesions. The Study was performed at the: HELIOS Heart Center/Siegburg, Germany (Prof. Eberhard Grube); Thoraxcenter Rotterdam (Prof. Patrick Serruys) and at the Institut Cardiovasculaire Paris Sud, France (Marie-Claude Morice, M.D.).
